EBGLYSS
GrowthmAbBLAINJECTIONINJECTABLE
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
EBGLYSS by Eli Lilly and Company is lebrikizumab-lbkz is an igg4 monoclonal antibody that binds with high affinity and slow off-rate to interleukin (il)-13 and allows il-13 to bind to il-13rα1 but inhibits human il-13 signaling through the il-4rα/il-13rα1 receptor complex. Approved for moderate-to-severe atopic dermatitis in adults, older, those therapies are not advisable. First approved in 2024.
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EBGLYSS (lebrikizumab-lbkz) is a monoclonal antibody that antagonizes interleukin-13, a key cytokine driver of type 2 inflammation. Approved by the FDA on September 13, 2024, it targets IL-13-mediated diseases. The drug is administered via injection and represents a novel mechanism for treating IL-13-driven conditions.
Growth
Early-stage product in growth phase with commercial infrastructure ramping; expect expanding field and marketing team size over next 2-3 years.
Mechanism of Action
Lebrikizumab-lbkz is an IgG4 monoclonal antibody that binds with high affinity and slow off-rate to interleukin (IL)-13 and allows IL-13 to bind to IL-13Rα1 but inhibits human IL-13 signaling through the IL-4Rα/IL-13Rα1 receptor complex. IL-13 is a naturally occurring cytokine that is involved in…
Indications (3)
Worked on EBGLYSS at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.